HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now von Schlam, Ilana, Swain, Sandra M.

Volltext

Overcoming Resistance to HER2-Directed Therapies in Breast Cancer von Schlam, Ilana, Tarantino, Paolo, Tolaney, Sara M

Volltext

Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases? von Schlam, Ilana, Tolaney, Sara M

Volltext

How I treat HER2-low advanced breast cancer von Schlam, Ilana, Tolaney, Sara M., Tarantino, Paolo

Volltext

Carfilzomib: A cause of drug associated thrombotic microangiopathy von Qaqish, Ibrahim, Schlam, Ilana M, Chakkera, Harini A, Fonseca, Rafael, Adamski, Jill

Volltext

Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? von Song, Fei, Tarantino, Paolo, Garrido-Castro, Ana, Lynce, Filipa, Tolaney, Sara M., Schlam, Ilana

Volltext

Application of NCCN guidelines in PD-L1 expression for patients with stage IV non-small cell lung cancer von Schlam, Ilana, Dyehouse, Karyn M., Ward, Patrick J.

Volltext

Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2 von Schlam, Ilana, Moges, Ruth, Morganti, Stefania, Tolaney, Sara M., Tarantino, Paolo

Volltext

Abstract OT-26-03: Racial disparities in CYP3A variants in the metabolism of ribociclib in breast cancer patients von Schlam, Ilana, Smith, D. Max, Chang, Ian, Dilawari, Asma, Peer, Cody, Sissung, Tristan, Tan, Ming, Figg, W. Douglas, Swain, Sandra M.

Volltext

Potential and Pitfalls of Pharmacovigilance Databases in Oncology von Schlam, Ilana, Ewer, Michael S., Swain, Sandra M.

Volltext

Aortic Insufficiency Secondary to Enterococcus faecalis Endocarditis in an HIV-Positive Patient von Schlam-Camhi, Ilana M., Layton, George, Cisneros-Cortes, Javier, Goldberg-Dalma, Benjamin A., Bucay, Moises

Volltext

Treatment of Severe Hypertriglyceridemia (500 to >/= 2000 mg/dL) in 636 Patients von Jarman, Michael, Rothschild, Matan, MD, Lee, Kevin, MD, Schlam, Ilana, MD, Mahida, Chris, MD, Makadia, Frini, MD, Milgrom, Alexander, MD, Min, Sarah, MD, Huda, Ali, MD, Goldenburg, Naila, MD, Wang, Ping, PhD, Glueck, C.J., MD

Volltext

Abstract 2718: Digital spatial profiling in HER2 positive breast cancer: The road to precision medicine von Schlam, Ilana, Church, Sarah E., Chaldekas, Krysta, Harris, Brent T., Hudson, Briana M., White, Andrew M., Swain, Sandra M.

Volltext

Abstract PD9-02: Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherap... von Lynce, Filipa, Mainor, Candace, Geng, Xue, Jones, Greg, Schlam, Ilana, Wang, Hongkun, Feger, Ute, Donahue, Renee, Toney, Nicole, Jochems, Caroline, Schlom, Jeffrey, Gallagher, Christopher, Nanda, Rita, Graham, Deena, Stringer-Reasor, Erica M, Denduluri, Neelima, Collins, Julie, Dilawari, Asma A, Chitalia, Ami, Tiwari, Shruti, Nunes, Raquel, Kaltman, Rebecca, Khoury, Katia, Gatti-Mays, Margaret, Swain, Sandra M, Parsons, Heather A., Pohlmann, Paula, Isaacs, Claudine

Volltext

Best of the year: Advanced breast cancer in 2023 von Schlam, Ilana, Chavez-MacGregor, Mariana

Volltext

The tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profiling von Schlam, Ilana, Church, Sarah E, Hether, Tyler D, Chaldekas, Krysta, Hudson, Briana M, White, Andrew M, Maisonet, Emily, Harris, Brent T, Swain, Sandra M

Volltext

Tolerability of capecitabine in difference racial/ethnic groups von Dower, Joshua, Salei, Yana, Dumas, Brett, Schlam, Ilana

Volltext

Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases von Pan, Stacey, Gadrey, Jayant Y., Sammons, Sarah, Lin, Nancy U., Tolaney, Sara M., Tarantino, Paolo, Schlam, Ilana

Volltext

Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next? von Schlam, Ilana, Dower, Joshua, Lynce, Filipa

Volltext

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study von Lynce, Filipa, Mainor, Candace, Donahue, Renee N., Geng, Xue, Jones, Greg, Schlam, Ilana, Wang, Hongkun, Toney, Nicole J., Jochems, Caroline, Schlom, Jeffrey, Zeck, Jay, Gallagher, Christopher, Nanda, Rita, Graham, Deena, Stringer-Reasor, Erica M., Denduluri, Neelima, Collins, Julie, Chitalia, Ami, Tiwari, Shruti, Nunes, Raquel, Kaltman, Rebecca, Khoury, Katia, Gatti-Mays, Margaret, Tarantino, Paolo, Tolaney, Sara M., Swain, Sandra M., Pohlmann, Paula, Parsons, Heather A., Isaacs, Claudine

Volltext